Zevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a report released on Wednesday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Guggenheim set a $21.00 target price on shares of Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 4th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Finally, Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.71.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $7.92 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a 50 day simple moving average of $7.95 and a two-hundred day simple moving average of $8.14. The stock has a market cap of $422.74 million, a price-to-earnings ratio of -4.02 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. As a group, analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. The trade was a 26.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in Zevra Therapeutics during the 4th quarter worth $53,000. XTX Topco Ltd acquired a new stake in Zevra Therapeutics during the 3rd quarter worth $94,000. China Universal Asset Management Co. Ltd. acquired a new stake in Zevra Therapeutics during the 4th quarter worth $94,000. Intech Investment Management LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth $95,000. Finally, Virtu Financial LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth $127,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.